



EAU Update on Bladder Cancer (BCa19)
“Challenging your knowledge of the EAU Guidelines”
17-18 May 2019, Turin, Italy

Steering committee: Joan Palou, Manfred Wirth
 Scientific committee: Marko Babjuk, Paolo Gontero, Andrea Necchi,
 Thomas Powles, Morgan Rouprêt, Arnulf Stenzl

Programme

Thursday, 16 May 2019 (OPTIONAL)

12.00 - 19.00 **Live surgery programme Molinette Hospital**

bca.uroweb.org/scientific-programme/live-surgery-day

Friday, 17 May 2019

08.00 - 08.15 **Introduction to the meeting and its format**
 J. Palou, Barcelona (ES)
 A. Stenzl, Tübingen (DE)

08.15 - 09.00 **Muscle Invasive Bladder Cancer (MIBC)**
 Chairs: A. Necchi, Milan (IT)
 A. Stenzl, Tübingen (DE)


08.15 - 08.30 **How much TURBT in patients with presumably MIBC prior to definitive therapy**
 F. Witjes, Nijmegen (NL)

08.30 - 08.45 **Bladder sparing approaches in MIBC: Towards a standard of care?**
 A. Bossi, Villejuif (FR)

08.45 - 09.00 **Neoadjuvant or adjuvant chemotherapy in localised MIBC?**
 T. Powles, London (GB)

09.00 - 12.30 **Case discussion 1 (Interactive voting session)**
 Faculty group 1: **Open or robotic radical cystectomy?** (Duel)
 Speakers: P. Gontero, Turin (IT)
 J. Palou, Barcelona (ES)

Faculty group 2: **Is there an oncological benefit of an extended lymphadenectomy in bladder cancer?**
 Speakers: M. Babjuk, Prague (CZ)
 F. Witjes, Nijmegen (NL)



Faculty group 3: **Choice of urinary diversion: An interdisciplinary perspective**

Speakers: A. Stenzl, Tübingen (DE)
M. Ribal, Barcelona (ES)

09.00 - 10.00 Faculty group 1 Sala 500(Plenary room)
Faculty group 2 Sala Madrid
Faculty group 3 Sala Londra

10.00 - 10.30 Coffee break

10.30 - 11.30 Faculty group 2 Sala 500(Plenary room)
Faculty group 3 Sala Madrid
Faculty group 1 Sala Londra

11.30 - 12.30 Faculty group 3 Sala 500(Plenary room)
Faculty group 1 Sala Madrid
Faculty group 2 Sala Londra

12.30 - 13.30 Lunch

13.30 - 14.00 Non-Muscle Invasive Bladder Cancer (NMIBC)

Chairs: M. Babjuk, Prague (CZ)
A. Stenzl, Tübingen (DE)

13.30 - 13.45 **The best TURBT in 2019: From optimal visualisation to optimal resection**
A. Breda, Barcelona (ES)

13.45 - 14.00 **Non-immunological intravesical treatment: What´s new?**
P. Black, Vancouver (CA)

14.00 - 17.30 Case discussion 2 (Interactive voting session)

Faculty group 1: **Sophisticated tumour visualisation: Clinical and prognostic implications**

Speakers: M. Babjuk, Prague (CZ)
B. Malavaud, Toulouse (FR)


Faculty group 2: **Standard and new techniques of TURBT**

Speakers: A. Breda, Barcelona (ES)
J. Dominguez Escrig, Valencia (ES)

Faculty group 3: **Adjuvant treatment in NMIBC: Where are we?**

Speakers: P. Black, Vancouver (CA)
F. Soria, Turin (IT)

14.00 – 15.00 Faculty group 1 Sala 500(Plenary room)
Faculty group 2 Sala Madrid
Faculty group 3 Sala Londra



15.00 – 16.00	Faculty group 2 Faculty group 3 Faculty group 1	Sala 500(Plenary room) Sala Madrid Sala Londra
16.00 – 16.30	Coffee break	
16.30 – 17.30	Faculty group 3 Faculty group 1 Faculty group 2	Sala 500(Plenary room) Sala Madrid Sala Londra

Saturday, 18 May 2019

08.00 - 09.00	Pathological assessment and molecular staging Chairs: P. Gontero, Turin (IT) A. Necchi, Milan (IT)
08.00 - 08.15	Molecular staging: How far from routine pathological assessment? E. Comperat, Paris (FR)
08.15 - 08.30	Variant (aberrant) pathologies: From diagnosis to optimal management P. Black, Vancouver (CA)
08.30 - 08.45	Genomic approach in BCa: From bench to bedside F. Liedberg, Malmö (SE)
08.45 - 09.00	Discussion Chairs: P. Gontero, Turin (IT) A. Necchi, Milan (IT) Panellists: E. Comperat, Paris (FR) P. Black, Vancouver (CA) F. Liedberg, Malmö (SE)
09.00 - 12.30	Case discussion 3 (Interactive voting session) Faculty group 1: Non-urothelial and aberrant urothelial histology: Its prognosis and impact on treatment decisions Speakers: S. Shariat, Vienna (AT) P. Black, Vancouver (CA) Faculty group 2: Radical cystectomy: How to handle the complications? Speakers: J. Palou, Barcelona (ES) P. Gontero, Turin (IT) Faculty group 3: Management and follow-up of low and intermediate risk tumours Speakers: F. Liedberg, Malmö (SE) F. Soria, Turin (IT)



09.00 - 10.00	Faculty group 1 Faculty group 2 Faculty group 3	Sala 500(Plenary room) Sala Madrid Sala Londra
10.00 - 10.30	Coffee break	
10.30 - 11.30	Faculty group 2 Faculty group 3 Faculty group 1	Sala 500(Plenary room) Sala Madrid Sala Londra
11.30 - 12.30	Faculty group 3 Faculty group 1 Faculty group 2	Sala 500(Plenary room) Sala Madrid Sala Londra
12.30 – 13.30	Lunch	
13.30 - 14.00	What´s new in diagnosing and staging of urothelial cancer? Chairs: P. Gontero, Turin (IT) A. Stenzl, Tübingen (DE)	
13.30 - 13.45	Novel urinary markers: Ready to overcome urine cytology and cystoscopy? L-M. Krabbe, Münster (DE)	
13.45 – 14.00	Multiparametric magnetic resonance imaging and staging in bladder cancer R. Faletti, Turin (IT)	
14.00 - 14.45	Update on medical therapies Chairs: J. Palou, Barcelona (ES) A. Stenzl, Tübingen (DE)	
14.00 - 14.15	Sequencing of new therapeutic options in metastatic urothelial cancer A. Necchi, Milan (IT)	
14.15 - 14.30	UTUC: biological and therapeutic rationale J. Baard, Amsterdam (NL)	
14.30 - 14.45	Emerging role of immunotherapy in neoadjuvant and adjuvant setting S. Shariat, Vienna (AT)	
14.45 - 15.30	Panel case discussion: Critical decision making in NMIBC Chair: P. Gontero, Turin (IT) Case presenter: F. Soria, Turin (IT) Panellists: M. Babjuk, Prague (CZ) F. Liedberg, Malmö (SE) A. Necchi, Milan (IT) J. Palou, Barcelona (ES)	
15.30 - 15.40	Close J. Palou, Barcelona (ES) A. Stenzl, Tübingen (DE)	